[A fosfomycin-gentamicin combination in the treatment of experimental endocarditis caused by Klebsiella pneumoniae producing type TEM-3 beta-lactamase]

Pathol Biol (Paris). 1989 Dec;37(10):1095-7.
[Article in French]

Abstract

The authors studied the activity of fosfomycin (FOS) and/or gentamicin (GEN) against a Klebsiella pneumoniae strain resistant to all beta-lactams--except cephamycins and imipenem--by production of a plasmid mediated extended broad-spectrum beta-lactamase-TEM-3, to all aminoglycosides--except gentamicin--by production of a plasmid mediated 6' aminoglycoside acetyltransferase IV, to sulfonamides and to tetracyclines. In vitro, the combination FOS (MIC = MBC = 32 mg/l) + GEN (MIC = MBC = 2) appeared indifferent (FIC = 0.75; FBC = 1). In vivo, on experimental endocarditis in rabbits, FOS alone was ineffective, GEN alone was active but only at high dose regimen, FOS - GEN combination was active as compared with controls. Fosfomycin - gentamicin combination may be an alternative in the therapy of severe infections due to multiresistant Enterobacteriacae.

MeSH terms

  • Animals
  • Drug Resistance, Microbial
  • Drug Therapy, Combination / pharmacology
  • Drug Therapy, Combination / therapeutic use
  • Endocarditis, Bacterial / drug therapy*
  • Female
  • Fosfomycin / pharmacology
  • Fosfomycin / therapeutic use*
  • Gentamicins / pharmacology
  • Gentamicins / therapeutic use*
  • In Vitro Techniques
  • Klebsiella Infections / drug therapy*
  • Klebsiella pneumoniae / enzymology*
  • Rabbits
  • beta-Lactamases / biosynthesis

Substances

  • Gentamicins
  • Fosfomycin
  • beta-Lactamases